This study investigates advanced solid tumors with a specific mutation called KRAS G12D. The purpose of this study is to understand more about how this condition affects people.
The study evaluates the safety and tolerability of an investigational medication called ASP3082. It looks at how people respond to this treatment.
- Who can participate: Adults aged 18 and older with advanced solid tumors can participate. Participants must have received prior standard therapy or be ineligible for it. They must also have at least one measurable lesion and meet specific health criteria.
- Study details: Participants will receive ASP3082, which may be combined with other treatments, through an infusion. In some cases, a placebo may be used. An inactive substance that looks like the investigational medicine but does not contain any medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand